OA 09.03 – TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI (WCLC 2017)

Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. Tsai, James Chih-Hsin Yang, Helena Yu, L. Horn, K. Lee, V. Haddad, M.M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, Geoffrey R. Oxnard

 HMPL-504_Ph1b2_NSCLC_Tagrisso_Combo_WCLC_2017_thumb

 

Venue: IASLC 18th World Conference on Lung Cancer in Yokohama, Japan
Session: OA 09 – EGFR TKI Resistance (ID 663)
Presenter: Myung-Ju Ahn
Date: Tuesday, October 17, 2017

 

For a summary of the data presented, please see the Chi-Med company overview presentation.